<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="199" ids="26708">Sodium</z:chebi>-<z:chebi fb="105" ids="17234">glucose</z:chebi> co-transporters are a family of <z:chebi fb="105" ids="17234">glucose</z:chebi> transporter found in the intestinal mucosa of the small intestine (SGLT-2) and the proximal tubule of the nephron (SGLT-1 and SGLT-2) </plain></SENT>
<SENT sid="1" pm="."><plain>They contribute to renal <z:chebi fb="105" ids="17234">glucose</z:chebi> reabsorption and most of renal <z:chebi fb="105" ids="17234">glucose</z:chebi> (about 90%) is reabsorbed by SGLT-2 located in the proximal renal tubule </plain></SENT>
<SENT sid="2" pm="."><plain>Selectively inhibiting activity of SGLT-2 is an innovative therapeutic strategy for treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> by enhancing urinary <z:chebi fb="105" ids="17234">glucose</z:chebi> excretion from the body </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore SGLT-2 inhibitors are considered to be potential <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> drugs with an unique mechanism </plain></SENT>
<SENT sid="4" pm="."><plain>This review will highlight some recent advances and structure-activity relationships in the discovery and development of SGLT-2 inhibitors including O-<z:chebi fb="0" ids="24400">glycoside</z:chebi>, C-<z:chebi fb="0" ids="24400">glycoside</z:chebi>, C, O-spiro <z:chebi fb="0" ids="24400">glycoside</z:chebi> and non <z:chebi fb="0" ids="24400">glycosides</z:chebi> </plain></SENT>
</text></document>